Antidepressive efficacy, safety, tolerability and genetic response predictors of lithium augmentation in Escitalopram-treated patients with major depression

Trial Profile

Antidepressive efficacy, safety, tolerability and genetic response predictors of lithium augmentation in Escitalopram-treated patients with major depression

Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Lithium (Primary) ; Escitalopram
  • Indications Major depressive disorder
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Acronyms ELIA
  • Most Recent Events

    • 30 Jan 2014 Planned End Date changed to 2 Feb 2011 as reported by German Clinical Trials Register record.
    • 13 Feb 2013 New source identified and integrated (DRKS00004551: German Clinical Trials Register).
    • 11 Aug 2012 Actual end date added as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top